JP2014514363A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014514363A5 JP2014514363A5 JP2014510481A JP2014510481A JP2014514363A5 JP 2014514363 A5 JP2014514363 A5 JP 2014514363A5 JP 2014510481 A JP2014510481 A JP 2014510481A JP 2014510481 A JP2014510481 A JP 2014510481A JP 2014514363 A5 JP2014514363 A5 JP 2014514363A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- peptide
- polysaccharide
- immunogenic composition
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims description 94
- 102000036639 antigens Human genes 0.000 claims description 94
- 108091007433 antigens Proteins 0.000 claims description 94
- 239000000203 mixture Substances 0.000 claims description 86
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 56
- 150000004676 glycans Chemical class 0.000 claims description 40
- 229920001282 polysaccharide Polymers 0.000 claims description 40
- 239000005017 polysaccharide Substances 0.000 claims description 40
- 230000000295 complement effect Effects 0.000 claims description 30
- 230000002163 immunogen Effects 0.000 claims description 26
- 230000028993 immune response Effects 0.000 claims description 19
- 230000005867 T cell response Effects 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 claims description 9
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 8
- 102000004169 proteins and genes Human genes 0.000 claims description 7
- 108090000623 proteins and genes Proteins 0.000 claims description 7
- -1 1-cyano-4-dimethylaminopyridinium tetrafluoroborate Chemical compound 0.000 claims description 6
- 229920002307 Dextran Polymers 0.000 claims description 6
- 239000000556 agonist Substances 0.000 claims description 6
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 6
- 230000036755 cellular response Effects 0.000 claims description 6
- 230000000139 costimulatory effect Effects 0.000 claims description 6
- 239000003431 cross linking reagent Substances 0.000 claims description 6
- 239000013604 expression vector Substances 0.000 claims description 6
- 102000037865 fusion proteins Human genes 0.000 claims description 6
- 108020001507 fusion proteins Proteins 0.000 claims description 6
- 239000003446 ligand Substances 0.000 claims description 6
- 244000052769 pathogen Species 0.000 claims description 6
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 claims description 5
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 claims description 5
- 235000012538 ammonium bicarbonate Nutrition 0.000 claims description 5
- 239000001099 ammonium carbonate Substances 0.000 claims description 5
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 claims description 5
- 206010022000 influenza Diseases 0.000 claims description 5
- JDNTWHVOXJZDSN-UHFFFAOYSA-N iodoacetic acid Chemical compound OC(=O)CI JDNTWHVOXJZDSN-UHFFFAOYSA-N 0.000 claims description 5
- 230000027455 binding Effects 0.000 claims description 4
- 229960002685 biotin Drugs 0.000 claims description 4
- 235000020958 biotin Nutrition 0.000 claims description 4
- 239000011616 biotin Substances 0.000 claims description 4
- 102000043871 biotin binding protein Human genes 0.000 claims description 4
- 108700021042 biotin binding protein Proteins 0.000 claims description 4
- 210000002421 cell wall Anatomy 0.000 claims description 4
- 229910052751 metal Inorganic materials 0.000 claims description 4
- 239000002184 metal Substances 0.000 claims description 4
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 230000001580 bacterial effect Effects 0.000 claims description 3
- 230000001939 inductive effect Effects 0.000 claims description 3
- 230000004044 response Effects 0.000 claims description 3
- 101710129138 ATP synthase subunit 9, mitochondrial Proteins 0.000 claims description 2
- 101710168506 ATP synthase subunit C, plastid Proteins 0.000 claims description 2
- 101710114069 ATP synthase subunit c Proteins 0.000 claims description 2
- 101710197943 ATP synthase subunit c, chloroplastic Proteins 0.000 claims description 2
- 101710187091 ATP synthase subunit c, sodium ion specific Proteins 0.000 claims description 2
- 108090001008 Avidin Proteins 0.000 claims description 2
- 102000014914 Carrier Proteins Human genes 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 108010034143 Inflammasomes Proteins 0.000 claims description 2
- 201000005702 Pertussis Diseases 0.000 claims description 2
- 108010090804 Streptavidin Proteins 0.000 claims description 2
- 102000002689 Toll-like receptor Human genes 0.000 claims description 2
- 108020000411 Toll-like receptor Proteins 0.000 claims description 2
- 239000012190 activator Substances 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 229960002235 anthrax antigen Drugs 0.000 claims description 2
- 239000011230 binding agent Substances 0.000 claims description 2
- 108091008324 binding proteins Proteins 0.000 claims description 2
- 102000023852 carbohydrate binding proteins Human genes 0.000 claims description 2
- 150000001720 carbohydrates Chemical class 0.000 claims description 2
- 102000019758 lipid binding proteins Human genes 0.000 claims description 2
- 150000002632 lipids Chemical class 0.000 claims description 2
- 102000005962 receptors Human genes 0.000 claims description 2
- 108020003175 receptors Proteins 0.000 claims description 2
- 108010038196 saccharide-binding proteins Proteins 0.000 claims description 2
- 230000001932 seasonal effect Effects 0.000 claims description 2
- 239000000758 substrate Substances 0.000 claims description 2
- 201000008827 tuberculosis Diseases 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 26
- 229920001184 polypeptide Polymers 0.000 claims 24
- 239000003053 toxin Substances 0.000 claims 2
- 231100000765 toxin Toxicity 0.000 claims 2
- 108700012359 toxins Proteins 0.000 claims 2
- ABFYEILPZWAIBN-UHFFFAOYSA-N 3-(iminomethylideneamino)-n,n-dimethylpropan-1-amine;hydrochloride Chemical compound Cl.CN(C)CCCN=C=N ABFYEILPZWAIBN-UHFFFAOYSA-N 0.000 claims 1
- 241000589291 Acinetobacter Species 0.000 claims 1
- 241000588923 Citrobacter Species 0.000 claims 1
- 241000193163 Clostridioides difficile Species 0.000 claims 1
- 241000588914 Enterobacter Species 0.000 claims 1
- 241000588724 Escherichia coli Species 0.000 claims 1
- 241000192125 Firmicutes Species 0.000 claims 1
- 241000588748 Klebsiella Species 0.000 claims 1
- 241000589516 Pseudomonas Species 0.000 claims 1
- 241000607142 Salmonella Species 0.000 claims 1
- 241000607720 Serratia Species 0.000 claims 1
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 239000002158 endotoxin Substances 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 238000002649 immunization Methods 0.000 claims 1
- 229920006008 lipopolysaccharide Polymers 0.000 claims 1
- 230000003278 mimic effect Effects 0.000 claims 1
- 229920000642 polymer Polymers 0.000 description 25
- 241001465754 Metazoa Species 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- KIJSBKNJFAUJFV-ZOBUZTSGSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-n-[2-[2-[2-(2-aminoethoxy)ethoxy]ethoxy]ethyl]pentanamide Chemical group N1C(=O)N[C@@H]2[C@H](CCCCC(=O)NCCOCCOCCOCCN)SC[C@@H]21 KIJSBKNJFAUJFV-ZOBUZTSGSA-N 0.000 description 1
- 241000203069 Archaea Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 150000001615 biotins Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 150000002373 hemiacetals Chemical class 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161484934P | 2011-05-11 | 2011-05-11 | |
| US61/484,934 | 2011-05-11 | ||
| US201261608168P | 2012-03-08 | 2012-03-08 | |
| US61/608,168 | 2012-03-08 | ||
| US201261609974P | 2012-03-13 | 2012-03-13 | |
| US61/609,974 | 2012-03-13 | ||
| PCT/US2012/037412 WO2012155007A1 (en) | 2011-05-11 | 2012-05-11 | Multiple antigen presenting immunogenic composition, and methods and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017105191A Division JP6502420B2 (ja) | 2011-05-11 | 2017-05-29 | 多重抗原提示免疫原性組成物、ならびにその方法および使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014514363A JP2014514363A (ja) | 2014-06-19 |
| JP2014514363A5 true JP2014514363A5 (https=) | 2015-06-25 |
| JP6152378B2 JP6152378B2 (ja) | 2017-06-21 |
Family
ID=47139675
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014510498A Active JP6366501B2 (ja) | 2011-05-11 | 2012-05-11 | 修飾ビオチン結合タンパク質、その融合タンパク質、および用途 |
| JP2014510481A Active JP6152378B2 (ja) | 2011-05-11 | 2012-05-11 | 多重抗原提示免疫原性組成物、ならびにその方法および使用 |
| JP2017105191A Active JP6502420B2 (ja) | 2011-05-11 | 2017-05-29 | 多重抗原提示免疫原性組成物、ならびにその方法および使用 |
| JP2018126516A Active JP6666389B2 (ja) | 2011-05-11 | 2018-07-03 | 修飾ビオチン結合タンパク質、その融合タンパク質、および用途 |
| JP2019052175A Pending JP2019104758A (ja) | 2011-05-11 | 2019-03-20 | 多重抗原提示免疫原性組成物、ならびにその方法および使用 |
| JP2020026905A Active JP7336402B2 (ja) | 2011-05-11 | 2020-02-20 | 修飾ビオチン結合タンパク質、その融合タンパク質、および用途 |
| JP2023133790A Active JP7679431B2 (ja) | 2011-05-11 | 2023-08-21 | 修飾ビオチン結合タンパク質、その融合タンパク質、および用途 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014510498A Active JP6366501B2 (ja) | 2011-05-11 | 2012-05-11 | 修飾ビオチン結合タンパク質、その融合タンパク質、および用途 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017105191A Active JP6502420B2 (ja) | 2011-05-11 | 2017-05-29 | 多重抗原提示免疫原性組成物、ならびにその方法および使用 |
| JP2018126516A Active JP6666389B2 (ja) | 2011-05-11 | 2018-07-03 | 修飾ビオチン結合タンパク質、その融合タンパク質、および用途 |
| JP2019052175A Pending JP2019104758A (ja) | 2011-05-11 | 2019-03-20 | 多重抗原提示免疫原性組成物、ならびにその方法および使用 |
| JP2020026905A Active JP7336402B2 (ja) | 2011-05-11 | 2020-02-20 | 修飾ビオチン結合タンパク質、その融合タンパク質、および用途 |
| JP2023133790A Active JP7679431B2 (ja) | 2011-05-11 | 2023-08-21 | 修飾ビオチン結合タンパク質、その融合タンパク質、および用途 |
Country Status (13)
| Country | Link |
|---|---|
| US (9) | US10766932B2 (https=) |
| EP (4) | EP3881836A1 (https=) |
| JP (7) | JP6366501B2 (https=) |
| KR (4) | KR102494245B1 (https=) |
| CN (4) | CN103648489A (https=) |
| AU (2) | AU2012253359B2 (https=) |
| BR (2) | BR112013028887B1 (https=) |
| CA (1) | CA2835628C (https=) |
| ES (2) | ES2864765T3 (https=) |
| MX (2) | MX2013013111A (https=) |
| RU (2) | RU2619176C2 (https=) |
| WO (2) | WO2012155007A1 (https=) |
| ZA (2) | ZA201308461B (https=) |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ521531A (en) * | 2000-02-28 | 2005-12-23 | Chiron S | Heterologous expression of neisserial proteins |
| US9125863B2 (en) * | 2008-05-22 | 2015-09-08 | Children's Medical Center Corporation | Synergistic immunogenic fusion protein-polysaccharide conjugate |
| JP2013525271A (ja) | 2010-03-12 | 2013-06-20 | チルドレンズ メディカル センター コーポレーション | 免疫原およびそのスクリーニング方法 |
| CN103648489A (zh) | 2011-05-11 | 2014-03-19 | 儿童医疗中心有限公司 | 多抗原提呈免疫原性组合物及其方法和用途 |
| WO2012164480A1 (en) * | 2011-05-30 | 2012-12-06 | National Institute Of Immunology | A vaccine composition capable of inducing memory antibody response from single point immunization |
| WO2013043643A1 (en) * | 2011-09-21 | 2013-03-28 | St. Jude Children's Research Hospital | Live, attenuated streptococcus pneumoniae strain and vaccine for protection against pneumococcal disease |
| EP2906720A4 (en) | 2012-10-10 | 2016-06-01 | Univ Arizona | MOLECULAR BASED SYSTEMS AND DEVICES AND METHOD FOR PRODUCING THEM |
| US11576958B2 (en) | 2013-02-07 | 2023-02-14 | Children's Medical Center Corporation | Protein antigens that provide protection against pneumococcal colonization and/or disease |
| WO2015065985A1 (en) * | 2013-10-31 | 2015-05-07 | Arizona Board Of Regents On Behalf Of Arizona State University | Chemical reagents for attaching affinity molecules on surfaces |
| WO2016044588A1 (en) | 2014-09-19 | 2016-03-24 | The Regents Of The University Of Michigan | Staphylococcus aureus materials and methods |
| CN104548101B (zh) * | 2015-01-31 | 2017-02-22 | 广东海大畜牧兽医研究院有限公司 | 一种诱导哺乳动物乳腺黏膜产生IgA的免疫增强剂及其制备方法和应用 |
| CN105646681B (zh) * | 2016-01-21 | 2021-07-16 | 浙江海隆生物科技有限公司 | 一种奶牛金黄色葡萄球菌α-溶血素亚单位疫苗的制备方法及应用 |
| US11446398B2 (en) | 2016-04-11 | 2022-09-20 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
| JP2019524639A (ja) * | 2016-05-04 | 2019-09-05 | ザ チルドレンズ メディカル センター コーポレーション | アビジン様タンパク質およびそれらの融合タンパク質を精製する方法 |
| US10751398B2 (en) * | 2016-10-07 | 2020-08-25 | Loyola University Chicago | Inflammasome activators and methods of use to treat tumors |
| US10738338B2 (en) | 2016-10-18 | 2020-08-11 | The Research Foundation for the State University | Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate |
| US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
| CN110366428B (zh) | 2016-12-30 | 2024-05-17 | Vaxcyte公司 | 具有非天然氨基酸的多肽-抗原缀合物 |
| US11951165B2 (en) | 2016-12-30 | 2024-04-09 | Vaxcyte, Inc. | Conjugated vaccine carrier proteins |
| KR102746901B1 (ko) | 2017-03-03 | 2024-12-26 | 옵시디안 테라퓨틱스, 인크. | Cd19 조성물 및 면역요법을 위한 방법 |
| US20180161433A1 (en) * | 2017-03-22 | 2018-06-14 | Timothy Andrew Erickson | Size tunable microbial mimetics for immunotherapy of thyroid carcinomas and solid tumors |
| AU2018243910B2 (en) * | 2017-03-28 | 2025-04-10 | The Children's Medical Center Corporation | A multiple antigen presenting system (MAPS)-based staphylococcus aureus vaccine, immunogenic composition, and uses thereof |
| US12090198B2 (en) * | 2017-05-22 | 2024-09-17 | The Children's Medical Center Corporation | Combined vaccine against mycobacterium tuberculosis |
| US10729763B2 (en) | 2017-06-10 | 2020-08-04 | Inventprise, Llc | Mixtures of polysaccharide-protein pegylated compounds |
| WO2018227177A1 (en) | 2017-06-10 | 2018-12-13 | Inventprise, Llc | Multivalent conjugate vaccines with bivalent or multivalent conjugate polysaccharides that provide improved immunogenicity and avidity |
| MX2019015524A (es) | 2017-06-23 | 2020-09-10 | Univ Maryland | Composiciones inmunogenicas. |
| US12178854B2 (en) | 2017-07-19 | 2024-12-31 | Children's Medical Center Corporation | Compositions and methods for treating diseases associated with an imprinting defect |
| WO2019075372A1 (en) * | 2017-10-13 | 2019-04-18 | The Research Foundation For The State University Of New York | COMPREHENSIVE VACCINE DESIGN AGAINST THE PROGRESSION OF COMMENSITY DISEASES |
| US12053486B2 (en) | 2018-03-09 | 2024-08-06 | Therazure LLC | Compositions for the treatment of infections in feet |
| CN108339115B (zh) * | 2018-05-11 | 2020-07-10 | 武汉博沃生物科技有限公司 | 使用重组载体蛋白的肺炎球菌联合疫苗及其制备方法 |
| WO2019241315A1 (en) | 2018-06-12 | 2019-12-19 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
| SG11202101973YA (en) * | 2018-09-12 | 2021-03-30 | Childrens Medical Ct Corp | Pneumococcal fusion protein vaccines |
| CN112969474A (zh) | 2018-09-12 | 2021-06-15 | 艾芬尼维克斯公司 | 多价肺炎球菌疫苗 |
| US20210386788A1 (en) | 2018-10-24 | 2021-12-16 | Obsidian Therapeutics, Inc. | Er tunable protein regulation |
| CN109400704B (zh) * | 2018-11-14 | 2020-07-21 | 珠海泰诺麦博生物技术有限公司 | 一种抗金黄色葡萄球菌α-溶血素的抗体及其应用 |
| MX2021010840A (es) | 2019-03-08 | 2022-01-19 | Obsidian Therapeutics Inc | Composiciones de anhidrasa carbónica 2 (ca2) humana y métodos de regulación ajustable. |
| US20220228168A1 (en) * | 2019-04-29 | 2022-07-21 | The Broad Institute, Inc. | Affinity-based multiplexing for live-cell monitoring of complex cell populations |
| JP2022537670A (ja) | 2019-06-12 | 2022-08-29 | オブシディアン セラピューティクス， インコーポレイテッド | Ｃａ２の組成物および調整可能な制御方法 |
| EP3983537A1 (en) | 2019-06-12 | 2022-04-20 | Obsidian Therapeutics, Inc. | Ca2 compositions and methods for tunable regulation |
| CN111518822B (zh) * | 2019-07-02 | 2022-08-09 | 江南大学 | 一种硫酸软骨素abc裂解酶突变体及其分泌表达的方法 |
| JP2021029171A (ja) * | 2019-08-23 | 2021-03-01 | 国立大学法人東京農工大学 | ブレビバチルス菌を用いた表層提示法 |
| WO2021046451A1 (en) | 2019-09-06 | 2021-03-11 | Obsidian Therapeutics, Inc. | Compositions and methods for dhfr tunable protein regulation |
| EP4054624A4 (en) * | 2019-11-05 | 2023-12-27 | Beth Israel Deaconess Medical Center, Inc. | MYCOBACTERIAL COMPOSITIONS AND BIOMARRKERS FOR USE IN TREATMENT AND MONITORING THERAPEUTIC RESPONSE |
| US20230340402A1 (en) * | 2019-12-27 | 2023-10-26 | Amolifescience Co., Ltd. | Cell culture substrate and manufacturing method thereof |
| US12534703B2 (en) | 2019-12-27 | 2026-01-27 | Amolifescience Co., Ltd. | Cell culture substrate and manufacturing method therefor |
| BR102020013216A2 (pt) * | 2020-06-26 | 2022-03-08 | Instituto Butantan | Processo de obtenção de vesículas apresentadoras de antígenos (vaa) que possibilita o acoplamento de um ou mais antígenos |
| WO2022035816A1 (en) | 2020-08-10 | 2022-02-17 | Inventprise, Llc | Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24f |
| CN116113644A (zh) * | 2020-09-14 | 2023-05-12 | 神州细胞工程有限公司 | 通过糖-冠状病毒rbd抗原缀合物提高免疫原性的方法 |
| US20240197853A1 (en) * | 2021-04-06 | 2024-06-20 | The Board Of Trustees Of The University Of Illinois | Multivalent cholera multiepitope fusion antigen (mefa) and methods of use |
| WO2023039108A1 (en) | 2021-09-08 | 2023-03-16 | Affinivax, Inc. | Coronavirus vaccine |
| MX2024002779A (es) | 2021-09-09 | 2024-06-11 | Affinivax Inc | Vacunas neumocócicas multivalentes. |
| WO2023069278A1 (en) * | 2021-10-20 | 2023-04-27 | Fina Biosolutions, Llc | Chemical reagents for the activation of polysaccharides in the preparation of conjugate vaccines |
| MX2024005327A (es) | 2021-11-02 | 2024-05-21 | Arvada Therapeutics Inc | Composiciones y metodos de dsg2. |
| US20250064910A1 (en) * | 2021-12-02 | 2025-02-27 | The Children's Medical Center Corporation | A maps vaccine targeting salmonella enterica serovars |
| WO2023192997A2 (en) * | 2022-03-31 | 2023-10-05 | The Children's Medical Center Corporation | Immunogenic compositions for b-cell recall response to a polysaccharide antigen |
| WO2024081929A1 (en) * | 2022-10-14 | 2024-04-18 | The Children's Medical Center Corporation | Multiple antigen presenting system (maps) cross-linked using a bifunctional fusion protein and its use in vaccines |
| WO2024081871A1 (en) * | 2022-10-14 | 2024-04-18 | The Children's Medical Center Corporation | Shigella multiple antigen presenting immunogenic composition and fusion proteins thereof |
| EP4622665A2 (en) | 2022-11-22 | 2025-10-01 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| CN115819624B (zh) * | 2022-12-16 | 2023-12-15 | 深圳华腾生物医药科技有限公司 | 一种重组融合蛋白及其制备方法和应用 |
| JP2026509511A (ja) * | 2023-03-16 | 2026-03-19 | アフィニバックス、インコーポレイテッド | 免疫原性組成物 |
| PE20252774A1 (es) | 2023-03-30 | 2025-12-22 | Pfizer | Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados y usos de estos |
| AU2024255922A1 (en) | 2023-04-14 | 2025-10-30 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| WO2024224266A1 (en) | 2023-04-24 | 2024-10-31 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| EP4705319A1 (en) | 2023-05-04 | 2026-03-11 | Affinivax, Inc. | Rhizavidin variants |
| TW202527906A (zh) | 2023-09-14 | 2025-07-16 | 美商輝瑞股份有限公司 | 包含經結合之肺炎鏈球菌莢膜醣抗原之佐劑化致免疫性組成物及其用途 |
| WO2025080776A2 (en) * | 2023-10-13 | 2025-04-17 | The Children's Medical Center Corporation | Vaccine compositions comprising sialic acid binding domain (sbd) proteins and use thereof to enhance immune response |
| WO2025186705A2 (en) | 2024-03-06 | 2025-09-12 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| WO2025193903A1 (en) | 2024-03-15 | 2025-09-18 | Affinivax, Inc. | Pneumococcal polysaccharide compositions and uses thereof |
| WO2025219908A2 (en) | 2024-04-19 | 2025-10-23 | Pfizer Inc. | Media and fermentation methods for polysaccharide production in bacterial cell culture |
| CN118421577B (zh) * | 2024-06-28 | 2024-10-01 | 华南理工大学 | 酪氨酸酶突变体及其用途 |
Family Cites Families (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US244420A (en) | 1881-07-19 | Stove pipe threadeb and beader | ||
| US3887699A (en) | 1969-03-24 | 1975-06-03 | Seymour Yolles | Biodegradable polymeric article for dispensing drugs |
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| PH19942A (en) | 1980-11-18 | 1986-08-14 | Sintex Inc | Microencapsulation of water soluble polypeptides |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4673641A (en) | 1982-12-16 | 1987-06-16 | Molecular Genetics Research And Development Limited Partnership | Co-aggregate purification of proteins |
| US4745051A (en) | 1983-05-27 | 1988-05-17 | The Texas A&M University System | Method for producing a recombinant baculovirus expression vector |
| DE3413608A1 (de) | 1984-04-11 | 1985-10-24 | Hoechst Ag, 6230 Frankfurt | Implantierbare zubereitungen von regulatorischen peptiden mit gesteuerter freisetzung und verfahren zu ihrer herstellung |
| US4879236A (en) | 1984-05-16 | 1989-11-07 | The Texas A&M University System | Method for producing a recombinant baculovirus expression vector |
| EP0279862B1 (en) | 1986-08-28 | 1993-11-03 | Teijin Limited | Cytocidal antibody complex and process for its preparation |
| NZ224422A (en) | 1987-05-05 | 1990-11-27 | Molecular Eng Ass | Composition adapted for intranasal immunisation against viral infection comprising a glycoprotein complexed with a lipid |
| US5229490A (en) | 1987-05-06 | 1993-07-20 | The Rockefeller University | Multiple antigen peptide system |
| US5179007A (en) | 1989-07-07 | 1993-01-12 | The Texas A & M University System | Method and vector for the purification of foreign proteins |
| FR2664905B1 (fr) | 1990-07-18 | 1994-08-12 | Agronomique Inst Nat Rech | Baculovirus modifie, son procede d'obtention, et vecteurs d'expression obtenus a partir dudit baculovirus. |
| US5516657A (en) | 1992-05-11 | 1996-05-14 | Cambridge Biotech Corporation | Baculovirus vectors for expression of secretory and membrane-bound proteins |
| US5287569A (en) | 1992-11-09 | 1994-02-22 | Johnson Wayne G | Portable shower apparatus |
| US5390111A (en) | 1993-11-12 | 1995-02-14 | General Electric Company | Method and system for processing cone beam data for reconstructing free of boundary-induced artifacts a three dimensional computerized tomography image |
| WO1995017515A1 (en) | 1993-12-23 | 1995-06-29 | University Technologies International Inc. | Methods of expressing proteins in insect cells and methods of killing insects |
| IL112372A (en) | 1994-02-07 | 2001-08-26 | Res Dev Foundation | Non-viral vector for the delivery of genetic information to cells |
| US6994855B1 (en) | 1994-08-22 | 2006-02-07 | The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | S. aureus fibrinogen binding protein gene |
| NZ304715A (en) | 1995-03-22 | 1999-07-29 | Jackson H M Found Military Med | Production of immunogenic constructs using organic cyanylating reagents to activate carbohydrates and then coupling the carbohydrate to a protein, peptide or hapten |
| SE506793C2 (sv) | 1996-09-19 | 1998-02-09 | Atlas Copco Rocktech Ab | Kopplingsstycke för användning vid samtidig jord- och/eller bergborrning med en övre rotationsslaganordning och en undre slaganordning |
| JP4469026B2 (ja) | 1996-10-31 | 2010-05-26 | ヒューマン ジノーム サイエンシーズ，インコーポレイテッド | Ｓｔｒｅｐｔｏｃｏｃｃｕｓ ｐｎｅｕｍｏｎｉａｅの抗原およびワクチン |
| EP0977588B1 (en) | 1997-04-24 | 2004-10-06 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Coupling of unmodified proteins to haloacyl or dihaloacyl derivatized polysaccharides for the preparation of protein-polysaccharide vaccines |
| US7060458B1 (en) * | 1997-08-14 | 2006-06-13 | Wyeth | Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics |
| WO1999012416A1 (en) | 1997-09-09 | 1999-03-18 | The Trustees Of Columbia University In The City Of New York | T-independent conjugate-vaccines |
| US6680195B1 (en) | 1997-11-26 | 2004-01-20 | Inhibitex, Inc. | Extracellular matrix-binding proteins from staphylococcus aureus |
| SE9900496D0 (sv) | 1999-02-12 | 1999-02-12 | Pharmatrix Ab | Vaccine formulation |
| US6398774B1 (en) | 1999-09-29 | 2002-06-04 | Heska Corporation | Intranasal delivery system |
| US8246945B2 (en) | 2000-04-06 | 2012-08-21 | University Of Arkansas | Methods and reagents for decreasing clinical reaction to allergy |
| US6919187B2 (en) | 2000-04-21 | 2005-07-19 | Corixa Corporation | Compounds and methods for treatment and diagnosis of chlamydial infection |
| DK2116257T3 (da) | 2000-08-09 | 2013-02-04 | Alk Abello As | Parenterale vaccineformuleringer og anvendelser deraf |
| GB0107658D0 (en) | 2001-03-27 | 2001-05-16 | Chiron Spa | Streptococcus pneumoniae |
| NZ536859A (en) | 2002-05-14 | 2007-11-30 | Chiron Srl | Mucosal combination vaccines for bacterial meningitis |
| CA2517439C (en) | 2003-03-07 | 2013-07-23 | Wyeth Holdings Corporation | Polysaccharide - staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections |
| US20060251675A1 (en) * | 2003-03-17 | 2006-11-09 | Michael Hagen | Mutant cholera holotoxin as an adjuvant and an antigen carrier protein |
| EP2311988A1 (en) | 2003-04-15 | 2011-04-20 | Intercell AG | S. pneumoniae antigens |
| BRPI0410423A (pt) | 2003-05-07 | 2006-06-06 | Sanofi Pasteur Inc | processo de imunogenicidade melhorada para vacinação meningocócica |
| CA2537900A1 (en) * | 2003-09-03 | 2005-04-28 | Dendritherapeutics, Inc. | Multiplex vaccines |
| US20050112139A1 (en) | 2003-10-23 | 2005-05-26 | Nmk Research, Llc | Immunogenic composition and method of developing a vaccine based on factor H binding sites |
| EP1708741B1 (en) | 2003-12-24 | 2016-03-30 | Aduro Biotech | Recombinant nucleic acid molecules encoding fusion proteins comprising antigens and bacterial secretory signal polypeptides, expression cassettes, and bacteria, and methods of use thereof |
| US20070128183A1 (en) | 2004-04-27 | 2007-06-07 | Intercell Ag | Td antigens |
| GB0410220D0 (en) * | 2004-05-07 | 2004-06-09 | Kirkham Lea Ann | Mutant pneumolysin proteins |
| EP1791961B1 (en) * | 2004-08-18 | 2011-06-08 | The Governors of the University of Alberta | Protein production method utilizing yebf |
| FI20041396A0 (fi) * | 2004-10-29 | 2004-10-29 | Vesa Pekka Hytoenen | Uudet mikrobiavidiinit |
| WO2006050571A1 (en) | 2004-11-11 | 2006-05-18 | Queensland University Of Technology | Chlamydia antigens and uses thereof |
| GB0428394D0 (en) | 2004-12-24 | 2005-02-02 | Chiron Srl | Saccharide conjugate vaccines |
| WO2006084467A1 (en) | 2005-02-11 | 2006-08-17 | Ace Biosciences A/S | Surface-located streptococcus pneumoniae polypeptides |
| US20090148894A1 (en) * | 2005-08-15 | 2009-06-11 | Broedel Sheldon E | Methods for optimizing the secretion of protein in prokaryotes |
| JP5135220B2 (ja) * | 2005-09-01 | 2013-02-06 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス ゲーエムベーハー アンド カンパニー カーゲー | 血清群ｃ髄膜炎菌を含む複数ワクチン接種 |
| US8162878B2 (en) | 2005-12-05 | 2012-04-24 | Medrad, Inc. | Exhaust-pressure-operated balloon catheter system |
| MX2008007292A (es) | 2005-12-08 | 2008-10-17 | Univ Louisville Res Found | Composiciones inmunoestimuladoras y metodos. |
| WO2007081583A2 (en) * | 2006-01-04 | 2007-07-19 | Children's Medical Center Corporation | Anti-pneumococcal preparations and methods of use |
| US7943133B2 (en) | 2006-02-02 | 2011-05-17 | Boston Biocom Llc | Mesothelin antibody protein fusions and methods of use |
| US20080032340A1 (en) | 2006-06-09 | 2008-02-07 | University Of Arizona | Peptide motifs for binding avidin or neutravidin |
| US8148084B2 (en) * | 2006-06-22 | 2012-04-03 | Dana-Farber Cancer Institute, Inc. | Diagnosis of autoimmune disease |
| CA2690973A1 (en) * | 2006-06-23 | 2007-12-27 | Paul M. Simon | Targeted immune conjugates |
| US7452985B2 (en) | 2006-08-17 | 2008-11-18 | Visgeneer, Inc. | Human Ron-related gene variant associated with cancers |
| WO2008152448A2 (en) * | 2006-12-21 | 2008-12-18 | Emergent Product Development Uk Limited | Streptococcus proteins, and their use in vaccination |
| WO2008084467A2 (en) | 2007-01-11 | 2008-07-17 | Nice Systems Ltd. | Branch ip recording |
| CN100579152C (zh) | 2007-01-29 | 2010-01-06 | 华为技术有限公司 | 一种播放集团彩铃的方法、系统及装置 |
| EP2468869B1 (en) | 2007-01-31 | 2015-03-18 | Pfenex Inc. | Bacterial leader sequences for increased expression |
| AU2008287286B2 (en) | 2007-04-13 | 2013-10-10 | The Board Of Regents Of The University Of Oklahoma | Mutants of cholesterol-dependent cytolysins and uses thereof |
| CA2690708A1 (en) | 2007-06-26 | 2008-12-31 | Glaxosmithkline Biologicals S.A. | Vaccine |
| GB0714963D0 (en) | 2007-08-01 | 2007-09-12 | Novartis Ag | Compositions comprising antigens |
| US20100260791A1 (en) | 2007-08-03 | 2010-10-14 | President And Fellows Of Harvard | Chlamydia antigens |
| WO2009021548A1 (en) * | 2007-08-10 | 2009-02-19 | Wacker Chemie Ag | Expression of full length igg and secretion into the culture medium of prokaryotic cells |
| BRPI0816103A2 (pt) | 2007-08-28 | 2020-08-18 | Japan Tobacco Inc. | método para ligar proteínas a carregadores por fazer uso de tamavidinas. |
| JP5658564B2 (ja) | 2007-08-31 | 2015-01-28 | ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ | ブドウ球菌肺疾患および状態に対する免疫に関連した方法および組成物 |
| US8916163B1 (en) | 2007-12-21 | 2014-12-23 | Vanderbilt University | Method for treating microbial infections |
| MX2011006922A (es) | 2008-12-24 | 2012-06-12 | Netherlands Vaccine Inst | Polipeptidos de neumolisina (ply) modificada a partir de streptococcus pneumonia. |
| EP2208787A1 (en) * | 2009-01-19 | 2010-07-21 | Université de Liège | A recombinant alpha-hemolysin polypeptide of Staphylococcus aureus, having a deletion in the stem domain and heterologous sequences inserted |
| EP3263128A3 (en) | 2009-04-14 | 2018-01-24 | GlaxoSmithKline Biologicals S.A. | Compositions for immunising against staphylococcus aureus |
| US8828953B2 (en) * | 2009-04-20 | 2014-09-09 | NaZura BioHealth, Inc. | Chemosensory receptor ligand-based therapies |
| SA110310528B1 (ar) | 2009-06-22 | 2014-07-02 | Wyeth Llc | التركيبات المولدة للمناعة لأنتيجينات ستافيلوكوكس أوريس |
| RU2580299C2 (ru) | 2009-06-29 | 2016-04-10 | Дженосеа Биосайенсиз, Инк. | Вакцины и композиции, направленные против streptococcus pneumoniae |
| CN101797381B (zh) | 2010-01-29 | 2012-05-23 | 中国人民解放军第三军医大学 | 乙肝病毒抗原与路易斯寡糖的复合物及其制备方法和应用 |
| EP2555794A4 (en) | 2010-04-05 | 2014-01-15 | Univ Chicago | COMPOSITIONS AND METHODS RELATING TO PROTEIN A (SPA) ANTIBODIES AS IMMUNE REACTION AMPLIFIERS |
| EP2563396A2 (en) * | 2010-04-30 | 2013-03-06 | Augmenta Biologicals LLC | Delivery proteins |
| CN103648489A (zh) | 2011-05-11 | 2014-03-19 | 儿童医疗中心有限公司 | 多抗原提呈免疫原性组合物及其方法和用途 |
| JP5833759B2 (ja) | 2012-07-24 | 2015-12-16 | パイオニア株式会社 | 面光源を有する照明モジュール及び照明システム |
| WO2014018904A1 (en) | 2012-07-26 | 2014-01-30 | Genocea Biosciences, Inc. | Fused antigen vaccines and compositions against streptococcus pneumoniae |
| US11576958B2 (en) | 2013-02-07 | 2023-02-14 | Children's Medical Center Corporation | Protein antigens that provide protection against pneumococcal colonization and/or disease |
| AU2018243910B2 (en) | 2017-03-28 | 2025-04-10 | The Children's Medical Center Corporation | A multiple antigen presenting system (MAPS)-based staphylococcus aureus vaccine, immunogenic composition, and uses thereof |
| CN112969474A (zh) | 2018-09-12 | 2021-06-15 | 艾芬尼维克斯公司 | 多价肺炎球菌疫苗 |
-
2012
- 2012-05-11 CN CN201280034406.0A patent/CN103648489A/zh active Pending
- 2012-05-11 RU RU2013154489A patent/RU2619176C2/ru active
- 2012-05-11 AU AU2012253359A patent/AU2012253359B2/en active Active
- 2012-05-11 MX MX2013013111A patent/MX2013013111A/es unknown
- 2012-05-11 JP JP2014510498A patent/JP6366501B2/ja active Active
- 2012-05-11 CN CN201280034719.6A patent/CN103732222B/zh active Active
- 2012-05-11 KR KR1020217009127A patent/KR102494245B1/ko active Active
- 2012-05-11 MX MX2013013112A patent/MX2013013112A/es unknown
- 2012-05-11 WO PCT/US2012/037412 patent/WO2012155007A1/en not_active Ceased
- 2012-05-11 EP EP21156431.5A patent/EP3881836A1/en active Pending
- 2012-05-11 CA CA2835628A patent/CA2835628C/en active Active
- 2012-05-11 RU RU2013154706A patent/RU2632651C2/ru active
- 2012-05-11 KR KR1020197025288A patent/KR102234933B1/ko active Active
- 2012-05-11 US US14/116,402 patent/US10766932B2/en active Active
- 2012-05-11 ES ES12782582T patent/ES2864765T3/es active Active
- 2012-05-11 JP JP2014510481A patent/JP6152378B2/ja active Active
- 2012-05-11 CN CN201810413217.3A patent/CN108840912B/zh active Active
- 2012-05-11 CN CN201810398905.7A patent/CN108714212B/zh active Active
- 2012-05-11 KR KR1020137032751A patent/KR102084509B1/ko active Active
- 2012-05-11 EP EP12781636.1A patent/EP2706991B1/en active Active
- 2012-05-11 BR BR112013028887-6A patent/BR112013028887B1/pt active IP Right Grant
- 2012-05-11 US US14/116,492 patent/US9499593B2/en active Active
- 2012-05-11 EP EP12782582.6A patent/EP2709603B1/en active Active
- 2012-05-11 WO PCT/US2012/037541 patent/WO2012155053A1/en not_active Ceased
- 2012-05-11 ES ES12781636T patent/ES2864764T3/es active Active
- 2012-05-11 EP EP21156712.8A patent/EP3912619A1/en active Pending
- 2012-05-11 KR KR1020137032789A patent/KR20140146993A/ko not_active Ceased
- 2012-05-11 AU AU2012253327A patent/AU2012253327B2/en active Active
- 2012-05-11 BR BR112013028892-2A patent/BR112013028892B1/pt active IP Right Grant
-
2013
- 2013-11-11 ZA ZA2013/08461A patent/ZA201308461B/en unknown
- 2013-11-11 ZA ZA2013/08465A patent/ZA201308465B/en unknown
-
2015
- 2015-11-19 US US14/946,372 patent/US10017548B2/en active Active
-
2017
- 2017-05-29 JP JP2017105191A patent/JP6502420B2/ja active Active
-
2018
- 2018-05-30 US US15/992,343 patent/US10611805B2/en active Active
- 2018-07-03 JP JP2018126516A patent/JP6666389B2/ja active Active
-
2019
- 2019-03-20 JP JP2019052175A patent/JP2019104758A/ja active Pending
-
2020
- 2020-02-10 US US16/785,937 patent/US11560410B2/en active Active
- 2020-02-20 JP JP2020026905A patent/JP7336402B2/ja active Active
- 2020-07-31 US US16/945,714 patent/US11981708B2/en active Active
-
2022
- 2022-10-13 US US18/046,485 patent/US11976097B2/en active Active
-
2023
- 2023-08-21 JP JP2023133790A patent/JP7679431B2/ja active Active
-
2024
- 2024-03-20 US US18/611,637 patent/US12545710B2/en active Active
- 2024-04-03 US US18/626,126 patent/US20250066429A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014514363A5 (https=) | ||
| RU2013154489A (ru) | Иммуногенная композиция презентации множественных антигенов, относящиеся к ней способы и применения | |
| JP5914344B2 (ja) | Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓ５型および８型の莢膜糖の精製 | |
| US7285289B2 (en) | Nanoparticle vaccines | |
| JP5286089B2 (ja) | ポリサッカライドを精製する方法 | |
| ES2707778T3 (es) | Inmunógenos polisacáridos conjugados con proteínas portadoras de E. coli | |
| CA2530363C (en) | Carrier proteins for vaccines | |
| US20080233181A1 (en) | Nanoparticle adjuvants for sub-unit vaccines | |
| JP2014517835A5 (https=) | ||
| JP2015535812A5 (https=) | ||
| TR201811681T4 (tr) | İmmünojenik bileşimler. | |
| Turbyfill et al. | Assembly, biochemical characterization, immunogenicity, adjuvanticity, and efficacy of Shigella artificial invaplex | |
| WO2020257317A1 (en) | Rationally engineered carrier proteins for vaccines | |
| Bacelo et al. | Xanthan gum as an adjuvant in a subunit vaccine preparation against leptospirosis | |
| Stefanetti et al. | Click chemistry applied to the synthesis of salmonella typhimurium o-antigen glycoconjugate vaccine on solid phase with sugar recycling | |
| US20120100165A1 (en) | Drug transporter, and adjuvant and vaccine each utilizing same | |
| Cryz Jr et al. | Synthesis and characterization of a polyvalent Escherichia coli O-polysaccharide-toxin A conjugate vaccine | |
| WO2017011338A1 (en) | Sortase-mediated coupling of immunogenic polysaccharide-protein conjugates and their use | |
| Xu et al. | Development of an enzyme-mediated, site-specific method to conjugate toll-like receptor 2 agonists onto protein antigens: toward a broadly protective, four component, group A streptococcal self-adjuvanting lipoprotein–fusion combination vaccine | |
| De Benedetto et al. | Investigation on sugar–protein connectivity in salmonella O-antigen glycoconjugate vaccines | |
| WO2017054635A1 (zh) | 一种流感嗜血杆菌融合蛋白及其构建方法与应用 | |
| AU2019299836A1 (en) | Improvements in immunogenic conjugates | |
| Weidenbacher et al. | Chemically modified bacterial sacculi as a vaccine microparticle scaffold | |
| Oloomi | Evaluation of the immunogenic property of NT H. influenzae protein D with Neisseria meningitidis OMV in BALB/c | |
| US20180161425A1 (en) | Novel protein structure used for efficient antibody production in immunization |